PGHL5,435.00

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,022 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
Returns
Return on Common Equity37.3412.3017.86
Return on Assets25.308.3312.10
Return on Capital Employed48.4114.7516.26
Return on Invested Capital68.34
Margins
EBITDA Margin26.5826.6727.38
Operating Margin24.2025.0625.73
Incremental Operating Margin23.8434.76
Pretax Margin23.7426.2235.50
Net Income Margin17.4619.5426.44
FCF Margin17.94
Additional
Effective Tax Rate26.4725.4825.53
Dvd Payout Ratio206.48
Sustainable Growth Rate-39.7612.3017.86
Incremental Operating Margin %23.8434.76
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.